Magellan Rx Pushes For Switching To Oncology Biosimilars
Executive Summary
Magellan Rx has launched a program to encourage a shift to lower-cost oncology biosimilars, ahead of their US market entry this year, building on what the PBM says has been a successful drive for some autoimmune conditions to be treated with biosimilar versions of infliximab.